Video Shorts

Major cardiovascular toxicities associated with the prostate cancer treatment include arrhythmias, atherosclerosis, myocardial Infarction, hypertension & cardiomyopathy. Toxicities vary with the type of agent used in Prostate Cancer Treatment.

Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.

Combination of CDK4/6 inhibitors & aromatase inhibitor is recommended for frontline treatment of Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Patients eventually develop disease progression which might be attributed to ESR1 mutations.

High risk disease is observed in 30% of Myeloma Cases. Identification of high-risk patients is important as proportion of high-risk cases increase with relapses and can lead to significant mortality.

Tissue-agnostic treatment based on shared genetic aberrations have provided a new direction in cancer treatment. Emerging clinical evidence indicates that many molecular aberrations can be common across tumor types with different site of origin.

Average at diagnosis of prostate cancer is ~65 years & patients usually have multiple co- morbidities and may be on treatment with multiple prescribed medications.

Majority of Myeloma patients are > 65 years of age at diagnosis & that makes Geriatric Assessment a critical for these patients. Historically we have focused on Cytogenetic & Biochemical evaluation but not so much on geriatric assessment.

Dr. Joseph Mikhael explains the triad of maintaining the patients on term Lenalidomide maintenance.

Need to maximise the response to hypomethylating agents: Standard of care for high-risk Myelodysplastic Syndromes is Hypomethylating agents. Average time to response is about 3 months with either Azacytidine or Decitabine.

Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasms show considerable heterogeneity with respect to presence of anemia , cytopenia & molecular features.